Soluble urokinase-type plasminogen activator receptor (SuPAR) in patients with Parkinson’s disease
Objective: The objective of this study was to assess if soluble urokinase-type plasminogen activator receptor (SuPAR) is elevated in patients with Parkinson's disease (PD). Background:…SARS CoV2 in older patients with Parkinson’s.
Objective: To review the clinical presentation and management of SARS-CoV 2 in older patients with Parkinson’s during the first wave of the pandemic in West…INTERLEUKIN 4 (IL-4),INTERLEUKIN 1α (IL-1α) AND CORTISOL SERUM LEVELS IN PARKINSON’S DISEASE PATIENTS UNDERGOING DANCE THERAPY
Objective: To identify changes in anti and pro-inflammatory cytokines and cortisol hormone levels in patients with Parkinson's disease undergoing dance therapy. Background: Parkinson’s disease(PD) pathophysiology…Clinical Outcomes in Parkinson’s with COVID 19 during the’ first wave’ in West Berkshire, United Kingdom (UK)
Objective: To review the outcomes of COVID 19 during the first wave in patients with Parkinson’s in West Berkshire, UK. Background: UK is one of…Post-Covid-19 Parkinson’s disease: a Brazilian case series.
Objective: To describe two patients with post-COVID-19 Parkinson’s disease (PD) and discuss their possible causes. Background: PD is a neurodegenerative disorder characterized by motor and…Ultrastructural Characterization of Monocytes in Parkinson’s Disease and GBA mutations
Objective: To identify morphological changes in circulating CD14+ monocytes in manifesting and non-manifesting carriers of mutations of the GBA gene and Parkinson’s disease (PD). Background: Mutations of…Mutations in GBA and LRRK2 are not associated with increased inflammatory markers
Objective: To assess central and peripheral cytokines among Parkinson's disease (PD) patients with mutations in the LRRK2 and GBA genes as well as among non-manifesting…CSF inflammatory cytokines and correlation with clinical features in early, untreated PD patients
Objective: The aims of the present study were to investigate the levels of inflammatory cytokines in the cerebrospinal fluid (CSF) of drug-naïve Parkinson's Disease (PD)…Disease progression characterized by motor performance, dopaminergic neurodegeneration and T cell infiltration in the transgenic hm2-α-SYN-39 mouse model of Parkinson´s disease
Objective: To study disease progression in the transgenic (tg) hm2-α-SYN-39 mouse model of Parkinson´s disease (PD) by assessment of motor performance, dopaminergic neurodegeneration and T…A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)
Objective: Assessment of efficacy and safety in subjects with Parkinson’s disease (PD) following treatment for 12 weeks with placebo or AKST4290, a highly specific and…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 25
- Next Page »